Necrostatin-1

Catalog No.S8037

Necrostatin-1 Chemical Structure

Molecular Weight(MW): 259.33

Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.

Size Price Stock Quantity  
USD 97 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 14 Publications

3 Customer Reviews

  • Cytosolic extracts or nuclear extracts were examined by Western blot analysis using Abs against p105/p50, p100/p52 and phospho-p65. Solid arrowhead indicates a non-specific band. A nuclear marker, PARP, and cytosolic marker, b-tubulin, were used to assess the purity of each fraction.

    J Cell Mol Med, 2015, 19(5): 1042-54 . Necrostatin-1 purchased from Selleck.

  • HCT16 was treated with or without AMDE-1 (2.5 μM), zVAD (20 μM), and/or necrostatin-1 (necro, 40 μM) for 48 hours. Cell death was measured. Values represent means ± SD from three independent experiments.

    PLoS One, 2015, 10(3): e0122083. Necrostatin-1 purchased from Selleck.

  • The influence of MAPK/NF-kB pathways and TNF-α/IL-8 factors on the survival of Beas-2B cells irradiated with 0.5 Gyα-particles. (A) The irradiated cells had no further co-culture with U937 cells. (B) The irradiated Beas-2B cells were further co-cultured with U937 cells for 24 h after irradiation. In some experiments, Beas-2B cells were pretreated with 10 μM of U0126, SB203580, or necrostatin-1 for 1 h before irradiation, U937 cells were pretreated with 10 μM BAY 11-7082 1 h prior to cell co-culture, or 1 μg/ml anti-TNF-a antibody, 2 μg/ml anti-IL-8 antibody, 40 nM SB225002 were added to the medium in the cell co-culture period. ***P < 0.001compared with the non-irradiation control. #P < 0.05 ##P < 0.01 compared with cor-responding α-irradiated cells.

    Mutation Research, 2016, 789:1-8.. Necrostatin-1 purchased from Selleck.

Purity & Quality Control

Choose Selective TNF-alpha Inhibitors

Biological Activity

Description Necrostatin-1 is a specific RIP1 (RIPK1) inhibitor and inhibits TNF-α-induced necroptosis with EC50 of 490 nM in 293T cells.
Features A powerful tool for characterizing the role of necroptosis with characterized primary target.
Targets
RIP1 [1]
(293T cells)
490 nM(EC50)
In vitro

Necrostatin-1 (1-100 μM) inhibits the autophosphorylation of overexpressed and endogenous RIP1.It is found RIP1 is the primary cellular target responsible for the antinecroptosis activity of Necrostatin-1. [1] Necrostatin-1 efficiently suppresses necroptotic cell death triggered by an array of stimuli in a variety of cell types. Necrostatin-1, previously identified as small-molecule inhibitor of necroptosis, inhibits RIP kinase-induced necroptosis and inhibits TNF-α-induced necroptosis in jurkat cells with EC50 of 490 nM. [2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 NGXZUGRE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MlLrOVDDqM7:TR?= NYC4Ro45OjUEoHi= NG\TfYhqdmirYnn0d{BOVVNvaX7keYNm\CClZXzsJIRm[XSq NHGydHkzPjR5MkeyNy=>
MEFs  NWLBeoM3S2WubDDWbYFjcWyrdImgRZN{[Xl? MnTNNVDjiIoQvF2= NFvObVI1QCCq MlPuSG1UVw>? NYfjT2NWcW6qaXLpeJMhgl[DRD3wdo9ud3SnZDDk[YF1cCCxZjDDUm9VOy2mZYDs[ZRm\CCPRV\z MWOyOlQ{Pzd6OR?=
BMDM  MXrGeY5kfGmxbjDBd5NigQ>? MkfrNVDDqM7:TR?= MnGyN|DDqG2rbh?= M2P6epBzd3SnY4TzJINmdGy|IH\yc40hXEGNST3pcoR2[2WmIFzETEBz\WynYYPl MV:yOlM5OTZyMR?=
NCI-H28 NV;1bI0xS2WubDDWbYFjcWyrdImgRZN{[Xl? NXLJc3RJOTEEoN88US=> M4jPSFI1yqCq M1vr[pBz\X[nboTzJGRCWEVvaX7keYNm\CC{ZXT1Z5Rqd25ib3[gUmNKNUh{ODDj[YxtKH[rYXLpcIl1gcLi Ml3RNlYxODRzM{i=
MiaPaCa-2 NHT0clZHfW6ldHnvckBCe3OjeR?= MViyNEDPxE1? M2TVclI1KGh? MmXx[IVkemWjc3XzJJRp\SCnYYLsfUBv\WO{b4TpZ{Bk\Wyucx?= M{POWFI3ODByNkC3
BxPC-3 NFXBdFlHfW6ldHnvckBCe3OjeR?= MnXQNlAh|ryP MWmyOEBp NI\5W3Zl\WO{ZXHz[ZMhfGinIHXhdox6KG6nY4LveIlkKGOnbHzz MVWyOlAxODZyNx?=
SGC-7901 MVrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NVLwUItGOzEEoN88US=> M32yWVHDqGh? M4H0fZN2eHC{ZYPz[ZMhd3ijbHnwcIF1cW5vbXXkbYF1\WRiY3XscEBl\WG2aB?= MX2yOVc3PzB5Nh?=
KMS-12-PE  M33UUGNmdGxiVnnhZoltcXS7IFHzd4F6 NIrLT4g3OCEQvF2= NEn0NHo2KGh? M3[xdIlvcGmkaYTzJHNJUy2rbnT1Z4VlKGOnbHyg[IVifGh? MWCyOVU{ODB7OB?=
L929-A  M{HBVmNmdGxiVnnhZoltcXS7IFHzd4F6 M4HLb|UxyqEQvF5CpC=> NIfCVGkzPCCq NVW3Nm93[myxY3vzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aB?= M335N|I2Ozl6NUSw
L929-N  M1rYXWNmdGxiVnnhZoltcXS7IFHzd4F6 M4n0U|UxyqEQvF5CpC=> Ml7SNlQhcA>? NITPc4FjdG:la4OgWG5H|rFvaX7keYNm\CClZXzsJIRm[XSq MWKyOVM6QDV2MB?=
L929-A  NVTDdGtiTnWwY4Tpc44hSXO|YYm= NEDobZE2OMLizszNxsA> MVyxNkBp NFvYb3FjdG:la4OgeIhmKGOuZXH2ZYdmKG:oIFPhd5Bie2VvMzDhcoQhWEGUUB?= MlH1NlU{QTh3NEC=
L929-N  MnjaSpVv[3Srb36gRZN{[Xl? NXjNSms6PTEEoN88UeKh MUWxNkBp MYficI9kc3NidHjlJINt\WG4YXflJI9nKEOjc4Dhd4UuOyCjbnSgVGFTWA>? NHK5O4MzPTN7OEW0NC=>
L929 M{TBO2Z2dmO2aX;uJGF{e2G7 M3exW|UxyqEQvF5CpC=> Mm\LNVIhcA>? NWTMSmc1cW6qaXLpeJMhXE6IzsGtbY5lfWOnZDDCbYQh[2ynYY\h[4U> MYmyOVM6QDV2MB?=
L929-A NFv6R3RHfW6ldHnvckBCe3OjeR?= NHvSO5M2OMLizszNxsA> NWCxcXIyOTJiaB?= NF;MXG5qdmirYnn0d{B1cGViVF7G{tEucW6mdXPl[EBtd3O|IH;mJI1qfG:laH;u[JJq[WxibXXtZpJidmVicHXycYVi[mmuaYT5 M2Wwb|I2Ozl6NUSw
L929 M3npOWNmdGxiVnnhZoltcXS7IFHzd4F6 M{XrRlMxyqEQvF2= Mo\ONeKhcA>? NYqxOHJycW6qaXLpeJMhXE6ILd8xMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>? MoWwNlUxQTV5NEK=
L929 NUC1dXNGS2WubDDWbYFjcWyrdImgRZN{[Xl? NUPzblk2OzEEoN88US=> M3nXUVHDqGh? M4LhXolvcGmkaYTzJHRPTi4QsT3pcoR2[2WmIHPs[YF3[WenIH;mJHRweG9iSR?= NVnyUVJoOjVyOUW3OFI>
Huh7 MlzxR4VtdCCYaXHibYxqfHliQYPzZZk> MUG1NEDDvU1? NX3XVnNDOjRxNEigbC=> NIC4SGtFVVOR NIfXT2xxemW4ZX70d{Bk\WyuIHTlZZRpKG:oIILB[GhEXiClbz3pcoZm[3SnZDDIeYg4KGOnbHzz M3\RdVI1QTd|MkSw
OHC MVzGeY5kfGmxbjDBd5NigQ>? MWqzNFDjiIoQvF2= NYL6dWlUTE2VTx?= M2nWcolv[3KnYYPld{Bvd2m|ZT3pcoR2[2WmIHPvcoRmdnOnZDDueYNt\Wl? M174NVI1QDd2N{O0
OHC NUjkc5hWTnWwY4Tpc44hSXO|YYm= Mo[5N|Ax6oDLzszN MorJSG1UVw>? M2j6WIRm[3KnYYPld{Bvd2m|ZT3pcoR2[2WmIIP3c4xt\W5iboXjcIVqyqB? MVqyOFg4PDd|NB?=
OHC M1rVe2Z2dmO2aX;uJGF{e2G7 NYHoTFE5OzBy4pEJ{txO MU\EUXNQ MVny[ZN2dHS|IHnuJIEhemWmdXP0bY9vKG:oIH7vbZNmNWmwZIXj[YQhWkmSMTDhcoQhWkmSMzDpcY12dm:obIXvdoV{[2WwY3W= NVXLUppDOjR6N{S3N|Q>
OHC M13vXGZ2dmO2aX;uJGF{e2G7 Mm\ZN|Ax6oDLzszN NX\2cXVoTE2VTx?= M3TKVYRqdWmwaYPo[ZMhdm:rc3WtbY5lfWOnZDDBUXBMKGGldHn2ZZRqd25? NHTIRWQzPDh5NEezOC=>
OHC NX[wO2R6TnWwY4Tpc44hSXO|YYm= NXfkc4loOzBy4pEJ{txO NHLUR3dFVVOR M1nOSolv[3KnYYPld{B1cGViboXtZoVzKG:oIHHwc5B1d3SrYzDPTGN{KHerdHjveZQh[Wy2ZYLpcochfGinIHzleoVteyCxZjDDR|gh[W[2ZYKgco9qe2ViZYjwc5N2emV? MoXDNlQ5PzR5M{S=
SK-Hep1 NUDjTY0yTnWwY4Tpc44hSXO|YYm= M2WxWVYx6oDLzszNxsA> MWixPQKBkWh? MYjicI9kc3QEoN8yMYxieGGlaH;u[U1qdmS3Y3XkJI1wenCqb3zv[4lk[WxiY3jhcodmNCClZXzsJIRm[XSqIHHu[EBRUSC3cIThb4U> NGLRPG4zPDh|Mk[wNi=>
SK-Hep1 MoWwSpVv[3Srb36gRZN{[Xl? M4jWclYx6oDLzszNxsA> NEjsclgyQOLCiXi= NGnPWWJqdmirYnn0d{DPui2OYYDhZ4hwdmVvaX7keYNm\CCuZXHrZYdmKG:oIFjNS2IuOcLi NFLkSHIzPDh|Mk[wNi=>
SK-Hep1 NHHE[4xHfW6ldHnvckBCe3OjeR?= NH\LXoE3OOLCid88UeKh M{TxNVE56oDLaB?= NUHxSHBj[myxY3vzxsDPui2uYYDhZ4hwdmVvbXXkbYF1\WRiUFHSJIFk[3WvdXzheIlwdiCjbnSgRWlHKHS{YX7zcI9k[XSrb36geI8hfGinIHP5eI9{d2{EoB?= NV6yVYhJOjR6M{K2NFI>
L-540  Ml;sSpVv[3Srb36gRZN{[Xl? M1ztSlYx6oDLzszt MWOx5qCKcA>? M1vKbZBz\X[nboTzJJRp\SCpZX7ldoF1cW:wIH;mJHJQWw>? NXPnTY5TOjR3NkG1NVk>
L-540  NHLGWmxHfW6ldHnvckBCe3OjeR?= MUm2NQKBkc7:bR?= NELs[XUy6oDLaB?= MnTWdJJmfmWwdIOgeIhmKG2rdH;jbI9v\HKrYXygcYVu[nKjbnWg[IVxd2yjcnn6ZZRqd25? NEXOSpQzPDV4MUWxPS=>
L-540  MWrD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2nkW|Yx6oDLzszt MYWx5qCKcA>? MnLPdoVlfWOnczD0bIUhT2m4aX7vd5RifC:Vb4Lh[oVvcWJvaX7keYNm\CClZXzsJIRm[XSq M{fvXFI1PTZzNUG5
AGS M3PaOWNmdGxiVnnhZoltcXS7IFHzd4F6 NX\hWW9bPjEkgJpOwI0> M4KyTFHjiImq MkOwdJJmfmWwdIOgd4hqc2:waX6tbY5lfWOnZDDj[YxtKGSnYYTo NIDrWYkzPDR4M{G5PS=>
NRK-52E  MlHWR4VtdCCYaXHibYxqfHliQYPzZZk> MYGyNEDPxE1? MmPNNlQhcA>? M3TFWpBzd3SnY4TzJINmdGy|IH\yc40h[2WubDDk[YF1cCClYYXz[YQh[nliaYPjbIVucWFiaX7qeZJ6 M1KxRlI1OzVzOES1
NRK-52E  Mm\hR4VtdCCYaXHibYxqfHliQYPzZZk> NVzuNWY2OjBizszN NVPFRldSOjRiaB?= M4HEc4lv[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDh[pRmeiCWTl[t{tEhW3SrbYXsZZRqd25iYX7kJGFVWCCGZYDs[ZRqd25? MXKyOFM2OTh2NR?=
NRK-52E  NGnjc3JE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MUCyNEDPxE1? NWTLOpdLOjRiaB?= NF\3eFlqdmirYnn0d{BqdmO{ZXHz[YQhTHKyMTDwdo91\WmwIHX4dJJme3Orb36gZYZ1\XJiVF7GMe6yKFO2aX31cIF1cW:wIHHu[EBCXFBiRHXwcIV1cW:w NXLoW|FMOjR|NUG4OFU>
L929 M3yzXGZ2dmO2aX;uJGF{e2G7 MXeyM|XDqM7:Zz;tcOKh NUjPb3J6OjUEoHi= MmX3doV3\XK|ZXSgeIhmKGG3dH;wbIFogSCrbnT1Z4VlKGK7IGTOSu6yKGGub37lJIF{KHenbHygZZMhXE6IzsJCpEvDqHqYQVS= M3Lk[VI{QTRzN{[5
L929 MnvGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LSdlIwPcLizsznM41tyqB? Mn\xNlTDqGh? NGWyXllz\X[ncoPld{B1cGViY3XscEBoem:5dHigbY5pcWKrdHnvckBidmRiY3XscEBl\WG2aDDpcoR2[2WmIHL5JHRPTs7zIHHsc45mKGG|IIflcIwh[XNiVF7G{tHDqCwEoIrWRWQ> NXTnSFhMOjN7NEG3Olk>
L929 MYXGeY5kfGmxbjDBd5NigQ>? M4i5dFLDqM7:Zz;tcOKh M17ZcFI1yqCq MUjwdo9ud3S|IHPhd5Bie2VvNjCodFIxMSCjY4Tpeol1gSCjbnSgdJJw[2G|cHHz[U03KGOuZXH2ZYdm MX:yN|k1OTd4OR?=
L929 MkPSSpVv[3Srb36gRZN{[Xl? MlfOOeKh|rypL33s MnSwNlTDqGh? Moe1Zoxw[2u|IIrWRWQhcW6mdXPl[EBv\WO{b4D0c5NqeyCjbnSgZZV1d3CqYXf5 M3T1RlI{QTRzN{[5
C6 Ml\tR4VtdCCYaXHibYxqfHliQYPzZZk> MWexJI1ud2xxTB?= NWO0[WVnOyCq MXTheJRmdnWjdHXzJHNpcWuxbnnuJIlv\HWlZXSg[4xqd22jIHPlcIwh\GWjdHi= MnHDNlM5PDB2NEG=
U87 MmOwR4VtdCCYaXHibYxqfHliQYPzZZk> MWixJI1ud2xxTB?= M{fkc|MhcA>? NHHWfHBifHSnboXheIV{KFOqaXvvcolvKGmwZIXj[YQh\2yrb33hJINmdGxiZHXheIg> NH\tNW0zOzh2MES0NS=>
C6 NHK3O|BEgXSxdH;4bYNqfHliQYPzZZk> MnfCNUBudW:uL1y= NIHJVFA{KGh? MmS2Zoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? MonPNlM5PDB2NEG=
U87 Ml;oR5l1d3SxeHnjbZR6KEG|c3H5 Ml\1NUBudW:uL1y= MY[zJIg> Mm\aZoxw[2u|IIPobYtwdmmwIHnu[JVk\WRibnXjdo9{cXN? NGrrW4gzOzh2MES0NS=>
C6 MYTGeY5kfGmxbjDBd5NigQ>? Mme1NUBudW:uL1y= MoTHNU42NTNiaB?= MlvBd5VxeHKnc4Pld{B1cGViZYjwdoV{e2mxbjDv[kBTUVBvMTDjZZV{\WRiYomgd4hqc2:waX6= NYnSbY1LOjN6NEC0OFE>
U87 M1r3XmZ2dmO2aX;uJGF{e2G7 Mnz5NUBudW:uL1y= MYSxMlUuOyCq M{TtRZN2eHC{ZYPz[ZMhfGinIHX4dJJme3Orb36gc4YhWkmSLUGgZ4F2e2WmIHL5JJNpcWuxbnnu MnzUNlM5PDB2NEG=
TE671 NF\zS4xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NV7IfJNCPDEkgJpOwIcwdW{EoB?= MUiyOEBp MlLQdoV{[3WnczDHXFE2NTB5MD3pcoR2[2WmIHzvd5Mhd2ZiY3XscEB3cWGkaXzpeJk> MVyyN|c1PDJ7Nh?=
RMS13 NYni[JpzS2WubDDWbYFjcWyrdImgRZN{[Xl? NFP5[3I1OOLCid88[{9udMLi MmTwNlQhcA>? NIThTnJz\XOldXXzJGdZOTVvMEewMYlv\HWlZXSgcI9{eyCxZjDj[YxtKH[rYXLpcIl1gQ>? MlXUNlM4PDR{OU[=
MEFs MXnDfZRwfG:6aXPpeJkhSXO|YYm= MVyyM|YwOjBizszN M1n0WVE5KGh? M2TrW4lvcGmkaYTzJHRPTs7zLXnu[JVk\WRiY3XscEBl\WG2aDDpckBT\WyDIFvPJG1GTnN? M{jPfVI{PzJ5NUix
MEFs MWLGeY5kfGmxbjDBd5NigQ>? NH[xSHozOMLizszN NGrXXIIyNzJxNDDo NUHJV5pUe3WycILld5NmeyCWTldOtU1qdmS3Y3XkJHJKWEtzIIDoc5NxcG:{eXzheIlwdg>? NVryPHlOOjN5Mke1PFE>
ΔN-Karpas 299  NIHBfJREgXSxdH;4bYNqfHliQYPzZZk> MmeyNlDDqM7:TR?= NXrnVIlpOTZiaB?= NV;h[W1PcW6qaXLpeJMhS0R|MD3pcoR2[2WmIHPlcIwh\GWjdHi= NI\uTIEzOzV2NUmzPC=>
MM.1S  NXrDZ4hrS3m2b4TvfIlkcXS7IFHzd4F6 MVy5NEDDvU1? NU\z[|hnOSCq MlK1Zoxw[2u|IFLBXUAyOS15MEiyJIlv\HWlZXSgdoFxcWRiY3XscEB{f2WubHnu[y=> NWfUfnlqOjN3MkexOVQ>
KMS-12-BM NFnIPI1EgXSxdH;4bYNqfHliQYPzZZk> M4HiO|kxKML3TR?= NFz2d3MyKGh? MXnicI9kc3NiQlHZJFEyNTdyOEKgbY5lfWOnZDDyZZBq\CClZXzsJJN4\WyuaX7n NXjGZpVTOjN3MkexOVQ>
HT-22  MVHD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MnzuNVDDqM7:TR?= M2\pXlEzyqCq M2rQcGROW09? MXjwdo91\WO2czDh[4FqdnO2IHfseZRidWG2ZT3pcoR2[2WmIHPlcIwh\GWjdHi= MXKyN|MxPzd3Mh?=
HT-22  Ml\aSpVv[3Srb36gRZN{[Xl? NV3PNZpXOjYEoN88US=> MXuw5qCUOzEEoH3pci=> NFrB[5NFVVOR M3fvOIlvcGmkaYTzJGVTUyCDY4TpeoF1cW:wIHnu[JVk\WRiYomg[4x2fGGvYYTl NHLLe3UzOzNyN{e1Ni=>
NIH3T3  NXPZT5JKTnWwY4Tpc44hSXO|YYm= NY\Ob5ZDOTBxNUCg{txO MnW1NU8{KGh? NIK4[nFidWWuaX;yZZRmeyCWTldOtU1lemm4ZX6gZ49ueGyneDDmc5Ju[XSrb36= NXruUFJuOjN{NkG2O|c>
SH-EP NIi0NHlCeG:ydH;zbZMhSXO|YYm= NVnJfYU3OTEkgJpOwG3DqA>? NHvYVmI4OuLCiXlCpC=> NGfuPXFqdmirYnn0d{BKSVBiaX7obYJqfG:{LTDhcoQhVGW6YYT1cZVu[WJvaX7keYNm\CCjcH;weI9{cXN? NXiyVmFEOjJ6OUCzNlI>
HL60 M1y0eGFxd3C2b4Ppd{BCe3OjeR?= M1PEbVYxKM7:TR?= M1nY[FEzKGh? NE\ETpJmdmijbnPld{B{cGmtb37pck1qdmS3Y3XkJIFxd3C2b4Ppdy=> NEH5bVgzOjh|N{[4PS=>
HL60/Adr MYPBdI9xfG:|aYOgRZN{[Xl? NEPxfXc3OCEQvF2= MorZNVIhcA>? NXLaR4F3\W6qYX7j[ZMhe2ira3;ubY4ucW6mdXPl[EBieG:ydH;zbZM> MlzONlI5Ozd4OEm=
K562 NInkUpNCeG:ydH;zbZMhSXO|YYm= NVT4fm0xPjBizszN NGLCWoQyOiCq Mora[Y5p[W6lZYOgd4hqc2:waX6tbY5lfWOnZDDhdI9xfG:|aYO= MofCNlI5Ozd4OEm=
K562/Adr  MWrBdI9xfG:|aYOgRZN{[Xl? M4SyNlYxKM7:TR?= M4OxOFEzKGh? M2fs[4VvcGGwY3XzJJNpcWuxbnnuMYlv\HWlZXSgZZBweHSxc3nz MmGzNlI5Ozd4OEm=
HL60 NFLrc3pHfW6ldHnvckBCe3OjeR?= NH;iWXA3OCEQvF2= M2HG[VEzKGh? Mlm3ZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? MnjJNlI5Ozd4OEm=
HL60/Adr M2jnZmZ2dmO2aX;uJGF{e2G7 NVPMbpN2PjBizszN NGG5cGMyOiCq NWP2UIky[XWpbXXueJMhfGinIHPhd5Bie2VvMzDhZ5Rqfmm2eR?= Mn\sNlI5Ozd4OEm=
K562 M2fOV2Z2dmO2aX;uJGF{e2G7 M1nkOVYxKM7:TR?= NXrCSGY5OTJiaB?= MoXrZZVodWWwdIOgeIhmKGOjc4Dhd4UuOyCjY4Tpeol1gQ>? M1zzcVIzQDN5Nki5
K562/Adr  NU\BWZlxTnWwY4Tpc44hSXO|YYm= M3XjeVYxKM7:TR?= NHnzO3AyOiCq M4\JbYF2\22nboTzJJRp\SClYYPwZZNmNTNiYXP0bZZqfHl? NF;ON|IzOjh|N{[4PS=>
HL60 M1G2S2Z2dmO2aX;uJGF{e2G7 M3;LUVYxKM7:TR?= Ml7hNVIhcA>? NYXDWIxPcW6lcnXhd4V{KHSqZTDhZ5Rqfmm2eTDv[kBk[XOyYYPld{wh[2G|cHHz[UA5KGGwZDC5 NY[yN4lSOjJ6M{e2PFk>
HL60/Adr M1vqWWZ2dmO2aX;uJGF{e2G7 MnfvOlAh|ryP NXm1OZE3OTJiaB?= MW\pcoNz\WG|ZYOgeIhmKGGldHn2bZR6KG:oIHPhd5Bie2W|LDDjZZNx[XOnIEigZY5lKDl? MWmyNlg{PzZ6OR?=
K562 MojXSpVv[3Srb36gRZN{[Xl? NHfYOnY3OCEQvF2= MXKxNkBp NHn6OYVqdmO{ZXHz[ZMhfGinIHHjeIl3cXS7IH;mJINie3Cjc3XzMEBk[XOyYYPlJFgh[W6mIEm= NVe4OGZiOjJ6M{e2PFk>
K562/Adr  Mk\VSpVv[3Srb36gRZN{[Xl? MY[2NEDPxE1? Ml\QNVIhcA>? M2rEPIlv[3KnYYPld{B1cGViYXP0bZZqfHlib3[gZ4F{eGG|ZYOsJINie3Cjc3WgPEBidmRiOR?= M361NlIzQDN5Nki5
L929sA NVzObIZqSXCxcITvd4l{KEG|c3H5 MWexNEDPxE1? MUGxJIg> M4LOT4lvcGmkaYTzJJRp\SCjcH;weI91cWNicnXzdI9ve2VidH:gWG5H NEOxdXozOjN4Mke2Oy=>
L929sA MXfBdI9xfG:|aYOgRZN{[Xl? Mo\uNVAh|ryP NI\WWpcyKGh? M3viUpJme2O3ZYOgZ4VtdHNiZYjwdoV{e2mwZzDSTXBMOc7WSVSg[pJwdSCWTl[tbY5lfWOnZDDhdI9xfG:|aYO= NYLkZZNnOjJ|NkK3Olc>
L929sA NYLnPXpPSXCxcITvd4l{KEG|c3H5 NWHNOXYzOTBizszN M3vENlEhcA>? MmTLZYJzd2ejdHXzJJRp\SCrboTldoFkfGmxbjDv[kBk[XOyYYPlMVghf2m2aDDGRWRF Mo\uNlI{PjJ5Nke=
TPC-1 MmXKR4VtdCCYaXHibYxqfHliQYPzZZk> NXy5dod[OTByIN88US=> M2j5PFI1KGh? NI[4em5FVVOR MVfpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MlfiNlIyOzZ6MUi=
8505c MmTRR4VtdCCYaXHibYxqfHliQYPzZZk> MXuxNFAh|ryP M4j5ZVI1KGh? MXLEUXNQ M4\5SIlv[3KnYYPld{Bk\WyudXzhdkB{fXK4aY\hcC=> MkD2NlIyOzZ6MUi=
SW13 M3[3b2NmdGxiVnnhZoltcXS7IFHzd4F6 Ml7GNVAxKM7:TR?= M1LVfFI1KGh? MYrEUXNQ MUXpcoNz\WG|ZYOgZ4VtdHWuYYKgd5Vzfmm4YXy= MWGyNlE{PjhzOB?=
Jurkat  NGex[5ZEgXSxdH;4bYNqfHliQYPzZZk> MlHVOVAwKDFyMD:yNFDDqM7:bR?= MY[xM|MhcA>? NXLFWJFzemWmdXPld:KhVmGnZ3zldoliKG[xd3zldokucW6mdXPl[EBkgXSxdH;4bYNqfHl? NYrJeXVKOjF3M{WwNlA>
Jurkat  M{Gw[WZ2dmO2aX;uJGF{e2G7 MV6yNFDDqM7:bR?= NX\WXnp[OzBibXnu MX7y[YR2[2W|wrDOZYVodGW{aXGg[o94dGW{aT3pcoR2[2WmIILlZYN1cX[nIH;4fYdmdiC|cHXjbYV{KCiUT2OpJIdmdmW{YYTpc44> NV25VIZCOjF3M{WwNlA>
HT-22 NF;2c3VEgXSxdH;4bYNqfHliQYPzZZk> Ml73NVAh|ryP MlG1NVIhcA>? M1m3[JBzd3SnY4TzJIFo[Wmwc4SgZ4VtdCCmZXH0bEBqdmS3Y3XkJIJ6KDYEoH3tc4wwVCCpbIX0ZY1ifGYEoB?= MUOxO|c3ODh4OR?=

... Click to View More Cell Line Experimental Data

Protocol

Kinase Assay:

[1]

+ Expand

RIP1 kinase assay:

Phosphorylation of RIP1 requires its kinase activity. Expression constructs of FLAGtagged wild-type (WT) or a kinase-inactive pointmutant of RIP1 (K45M) are are transfected into 293T cells and RIP1 kinase assay is performed as described in the Methods in the presence of [γ-32P]ATP for 30 min at 30℃. Samples are subjected to SDS-PAGE and RIP1 band is visualized by autoradiography. Relative intensities of radioactive bands are quantified and are shown (ratio) in this and all other autoradiographs. In parallel to kinase reactions, a sample of beads is subjected to western blot analysis using anti-RIP1 antibody to ensure equal protein amounts in kinase reactions.
Cell Research:

[2]

+ Expand
  • Cell lines: Jurkat, BALB/c 3T3, SV40-transformed MEF, L929
  • Concentrations: 0.01-100 μM
  • Incubation Time: --
  • Method:

    Cells are seeded in 96-well plates (white plates for luminescent assays; black plates for fluorescent assays; clear plates for MTT assay) at the density of 5,000-10,000 cells per well for adherent cells or 20,000-50,000 cells per well for suspension cells in 100 μl of the appropriate phenol red-free media. After incubation, we determined cell viability using one of the following methods. For the ATP assay, we used luminescence-based commercial kits and analyzed luminescence using a Wallac Victor II plate reader. For Sytox assay, we incubated cells with 1 μM Sytox Green reagent for 30 min at 37℃, and then performed fluorescent reading. Subsequently, we added 5 μl of 20% Triton X-100 solution into each well to produce maximal lysis and incubated cells for 1 h at 37℃, then performed the second reading. We calculated the ratio of values before and after Triton treatment and normalized it to the relevant controls not subjected to cytotoxic stimuli, as indicated in figure legends. For the MTT assay, we used the CellTiter 96 AQueous Non-Radioactive Cell Proliferation Assay kit. For PI exclusion assays, we added 2 μg/ml PI into the medium and immediately analyzed samples using FACSCalibur. For PI-annexin V assay we used the ApoAlert Annexin V-EGFP Apoptosis Kit. For DioC6 staining, we incubated cells with 40 nM DiOC6 for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. For ROS analysis, we incubated cells with 5 μM dihydroethidium for 30 min at 37 ℃, washed once and analyzed in FACSCalibur. EM analyses are performed at the Harvard Medical School EM facility. We acquired bright-field images of the cells using an Axiovert 200 microscope.


    (Only for Reference)

Solubility (25°C)

In vitro DMSO 51 mg/mL warmed (196.66 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+45% PEG 300+ddH2O
For best results, use promptly after mixing.
10mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 259.33
Formula

C13H13N3OS

CAS No. 4311-88-0
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

TNF-alpha Signaling Pathway Map

Related TNF-alpha Products0

Tags: buy Necrostatin-1 | Necrostatin-1 supplier | purchase Necrostatin-1 | Necrostatin-1 cost | Necrostatin-1 manufacturer | order Necrostatin-1 | Necrostatin-1 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID